Purpose. To compare morphologic changes in human trabecular meshwork (TM) after selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT). Design. Laboratory evaluation of ex vivo human eye TM after laser trabeculoplasty. Methods. Corneoscleral rims from human cadaver eyes were sectioned and treated with varying powers of either SLT or ALT. Specimens were examined using light microscopy, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). Results. TEM of SLT at all powers resulted in disrupted TM cells with cracked and extracellular pigment granules. SEM of SLT samples treated at high power revealed tissue destruction with scrolling of trabecular beams. SEM of ALT-treated tissue showed increasing destruction with exposure to higher power. The presence or absence of "champagne" bubbles during SLT did not alter the histologic findings. Conclusions. SLT-treated human TM revealed disruption of TM cells with cracked, extracellular pigment granules, particularly at higher treatment powers. Tissue scrolling was noted at very high SLT energy levels. ALT-treated tissue showed significant damage to both the superficial and deeper TM tissues in a dose-dependent fashion. Further studies are needed to guide titration of treatment power to maximize the IOP-lowering effect while minimizing both energy delivered and damage to target tissues.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443779 | PMC |
http://dx.doi.org/10.1155/2015/476138 | DOI Listing |
Graefes Arch Clin Exp Ophthalmol
January 2025
Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Japan.
Indian J Ophthalmol
December 2024
Department of Ophthalmology, Sri Sathya Sai Institute of Higher Medical Sciences, Prasanthigram, Andhra Pradesh, India.
Purpose: To assess the effectiveness of selective laser trabeculoplasty (SLT) in Indian eyes with open-angle glaucoma (OAG).
Settings And Design: Single-center, prospective, interventional study.
Methods: Patients undergoing SLT from January 2014 to June 2018 for OAG were included in the study.
Can J Ophthalmol
December 2024
Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia, Canada.
Objective: To conduct a pilot study to evaluate and compare the 24-hour habitual intraocular pressure (IOP) and ocular perfusion pressure (OPP) fluctuation in glaucoma patients treated with medical therapy, selective laser trabeculoplasty (SLT) or trabeculectomy.
Design: Pilot study.
Participants: Criteria for inclusion were patients aged 18 years or older with well-controlled IOP with either maximum tolerated medical therapy, previous SLT, or previous trabeculectomy.
Ophthalmol Glaucoma
December 2024
Ruiz Department of Ophthalmology and Visual Science, McGovern Medical School at The University of Texas Health Science Center at Houston.
Objective: This study investigates the incidence and causes of diagnostic changes from primary open angle glaucoma suspect (POAGS) to primary open angle glaucoma (POAG), and vice versa, in clinical practice.
Design: This is a retrospective, single site, case-control study.
Participants: It includes patients over age 40 diagnosed with either POAG or POAGS between 2013-2020.
Cureus
November 2024
Department of Ophthalmology, George Washington University School of Medicine and Health Sciences, Washington, D.C., USA.
Purpose: To evaluate the effectiveness of selective laser trabeculoplasty (SLT) in reducing intraocular pressure (IOP) and medication use in treated and untreated eyes of angle recession glaucoma (ARG) patients within a year post procedure.
Methods: A retrospective chart review was conducted on nine ARG patients treated with SLT at George Washington University between January 1, 2008, and January 1, 2022. Patients were excluded if they had no ARG diagnosis, did not undergo SLT, lacked follow-up within one year after SLT, or had undergone laser or glaucoma surgery in the treated or untreated eye within 12 months before SLT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!